Evolus Inc (NASDAQ:EOLS) Receives $26.67 Average Target Price from Brokerages

Evolus Inc (NASDAQ:EOLS) has received a consensus recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $26.67.

A number of analysts recently commented on the company. Zacks Investment Research lowered EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Wells Fargo & Co assumed coverage on Establishment Labs in a research note on Friday, June 28th. They issued an “outperform” rating and a $29.00 price target for the company. SunTrust Banks raised their price target on Smartsheet to $56.00 and gave the stock a “positive” rating in a research note on Wednesday, March 20th. They noted that the move was a valuation call. HC Wainwright reiterated a “buy” rating and issued a $39.00 price objective on shares of MacroGenics in a report on Thursday, April 4th. Finally, Mizuho set a $31.00 price objective on Evolus and gave the stock a “buy” rating in a report on Monday, May 20th.

In related news, Director David N. Gill purchased 2,000 shares of Evolus stock in a transaction dated Thursday, June 13th. The stock was purchased at an average cost of $13.65 per share, for a total transaction of $27,300.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp Alphaeon sold 5,307,940 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $19.25, for a total value of $102,177,845.00. The disclosure for this sale can be found here. In the last quarter, insiders acquired 1,931,327 shares of company stock valued at $37,157,482.

Large investors have recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Evolus by 50.0% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Evolus by 48.9% during the first quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock valued at $39,000 after acquiring an additional 569 shares in the last quarter. Pearl River Capital LLC increased its holdings in shares of Evolus by 217.7% during the first quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock valued at $44,000 after acquiring an additional 1,306 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Evolus by 8,877.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock valued at $45,000 after acquiring an additional 1,953 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of Evolus during the first quarter valued at $83,000. Hedge funds and other institutional investors own 14.41% of the company’s stock.

EOLS stock traded down $0.03 on Friday, reaching $15.69. The company’s stock had a trading volume of 238,531 shares, compared to its average volume of 569,972. The company has a fifty day moving average price of $14.48. Evolus has a 12-month low of $10.22 and a 12-month high of $30.25. The stock has a market capitalization of $429.67 million, a price-to-earnings ratio of -9.99 and a beta of 4.79. The company has a current ratio of 14.80, a quick ratio of 14.52 and a debt-to-equity ratio of 0.96.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.11). On average, equities analysts expect that Evolus will post -2.92 EPS for the current year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: What does a bar chart display?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.